Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Share-based Compensation (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Share-based Compensation for 7 consecutive years, with $14.5 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 4.74% to $14.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $59.9 million through Dec 2025, up 8.89% year-over-year, with the annual reading at $59.9 million for FY2025, 8.89% up from the prior year.
  • Share-based Compensation for Q4 2025 was $14.5 million at Kymera Therapeutics, down from $15.8 million in the prior quarter.
  • The five-year high for Share-based Compensation was $15.8 million in Q3 2025, with the low at -$16.0 million in Q4 2021.
  • Average Share-based Compensation over 5 years is $9.7 million, with a median of $11.0 million recorded in 2023.
  • Peak annual rise in Share-based Compensation hit 762.35% in 2021, while the deepest fall reached 975.42% in 2021.
  • Over 5 years, Share-based Compensation stood at -$16.0 million in 2021, then skyrocketed by 155.7% to $8.9 million in 2022, then grew by 22.33% to $10.9 million in 2023, then grew by 26.62% to $13.8 million in 2024, then increased by 4.74% to $14.5 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $14.5 million, $15.8 million, and $15.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.